Getting started

Which GLP-1 Is Right for Me? How Doctors Decide

What the guidelines actually say about choosing between semaglutide, tirzepatide, orforglipron and liraglutide, plus the seven practical factors that usually settle it, including the one clinicians rarely say out loud.

Last verified September 14, 2026·10 sources cited·Wegovy Zepbound

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

People expect this decision to be a ranking. It is closer to a matching exercise.

The guidelines narrow the field to two molecules and then go quiet. Everything after that is about which approved indication you actually meet, what your plan will pay for, and which dosing format you will realistically stick with for years.

What do the guidelines actually say?

Less than you might hope, and more clearly than you might expect.

The American Diabetes Association’s 2026 Standards of Care, recommendation 8.18, states that in people with diabetes and overweight or obesity, “the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide), especially considering their added weight-independent benefits.” That is graded evidence level A [1].

Recommendation 8.16 adds that when choosing glucose-lowering medications for people with type 2 diabetes and overweight or obesity, prioritize medications with a beneficial effect on weight [1].

What the guideline does not do is pick between semaglutide and tirzepatide. It lists them together.

It does, however, say something unusually candid about the real world: GLP-1 receptor agonists and tirzepatide “are the preferred agents in individuals with stable insurance coverage” [1]. That qualifier is doing a lot of work.

What does the trial data show about effect size?

The ADA’s Table 8.1 summarizes obesity pharmacotherapy in people with type 2 diabetes, and it is worth reading carefully because the entries come from different trials [1]:

Medication	Dose and weight loss from baseline	Time frame
Tirzepatide	15 mg weekly: 14.7%; 10 mg weekly: 12.8%	72 weeks
Semaglutide	2.4 mg weekly: 9.6%; 1.0 mg weekly: 7%	56 weeks
Liraglutide	3.0 mg daily: 6%; 1.8 mg daily: 4.7%	56 weeks
Naltrexone/bupropion ER	16/180 mg twice daily: 5%	56 weeks
Phentermine/topiramate ER	15/92 mg daily: 9.8%; 7.5/46 mg daily: 7.8%	56 weeks
Orlistat	120 mg three times daily: 9.6%	52 weeks

Read the time frames, not just the percentages: the tirzepatide row is measured at 72 weeks and the semaglutide row at 56 weeks, so the gap between them is not a like-for-like comparison. These are separate trials in people with type 2 diabetes, not a head-to-head comparison, and effect sizes in people without diabetes are generally larger. Direct comparisons belong in the clinical trials lane, not here. What this table establishes for a first appointment is the broad tier structure: the incretin drugs sit well above the older oral agents.

Factor 1: which indication do you actually meet?

This is the first filter and it eliminates most options immediately.

Weight management, adults: Wegovy injection, Wegovy tablets, Zepbound, Foundayo, Saxenda [2][3][4][5]. Foundayo was approved on April 1, 2026, making it the newest of the five [11].

Weight management, age 12 and up: Wegovy injection (obesity, BMI at or above the 95th percentile for age and sex in the trial) and Saxenda (obesity, body weight over 60 kg) only [2][5]. Zepbound’s label states safety and effectiveness have not been established in pediatric patients [3]. Foundayo is adults only [4].

Moderate to severe obstructive sleep apnea in adults with obesity: Zepbound only, at 10 mg or 15 mg maintenance [3].

Cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight: Wegovy injection and Wegovy tablets [2].

Noncirrhotic MASH with moderate to advanced (F2-F3) fibrosis: Wegovy injection only, under accelerated approval [2].

Type 2 diabetes: Ozempic injection, Rybelsus and Ozempic tablets, Mounjaro, Trulicity [6][7][8][10]. Mounjaro and Trulicity go down to age 10 [7][8].

If you have sleep apnea and no coverage for weight-loss drugs, that single row changes the whole conversation.

Factor 2: what will your plan pay for?

The ADA’s “stable insurance coverage” qualifier is the honest version of this.

Business Group on Health’s 2026 GLP-1 survey of 105 large employers, fielded in February and March 2026, found that only 67 percent covered GLP-1s for weight management at all, and that employers who do cover them use strategies including “validating clinical eligibility via objective biometric data, requiring participation in a weight management program to receive coverage, limiting prescribing to specific providers and excluding certain medications from the formulary” [9]. That last item is the one that decides which molecule you get. Plans also use step therapy, meaning you may be required to try the plan’s preferred product first regardless of which one your clinician would pick.

The direction of travel is worth knowing before you build a plan around one product: in the same survey, only 72 percent of employers currently covering GLP-1s for weight management said they were likely to continue in 2027 [9].

Formularies move. Large numbers of patients have been shifted between semaglutide and tirzepatide mid-treatment when a plan changed its preferred product at the plan year boundary. Asking “which one is preferred on my plan this year” before the prescription is written saves weeks.

Factor 3: injection or tablet?

As of September 2026 there are genuine oral options for weight, which there were not two years ago.

Oral, weight-indicated:

Wegovy tablets, 25 mg daily maintenance after a 90-day ladder [2]
Foundayo (orforglipron), up to 17.2 mg daily [4]

Oral, diabetes only: Rybelsus (3, 7, 14 mg) and Ozempic tablets (starting 1.5 mg). The label notes the two brands “are not substitutable on a mg-to-mg basis” [6].

The practical difference between the two oral weight options is large. Every oral semaglutide product is labeled to be taken on an empty stomach in the morning with no more than 4 ounces of water, swallowed whole, with at least a 30-minute wait before food, other beverages or other oral medicines [2][6]. Foundayo is labeled to be taken with or without food, swallowed whole, one tablet per day, with no water or waiting rule [4].

For someone who takes a morning thyroid tablet, or who cannot reliably wait 30 minutes before coffee, that is often the deciding factor.

Foundayo trades that flexibility for a different constraint, though, and it belongs in the same conversation: its label caps the dosage at 9 mg once daily when a strong CYP3A4 inhibitor is taken alongside it, and advises avoiding strong CYP3A4 inducers [4]. For someone on several interacting medicines, the oral semaglutide timing rule may be the easier of the two problems.

Injectable frequency: weekly for Wegovy, Ozempic, Zepbound, Mounjaro and Trulicity; daily for Saxenda [2][3][5][7][8][10].

Wegovy’s label also includes instructions for switching between its injection and tablet forms in either direction: one week after stopping the 2.4 mg injection, start 25 mg tablets; the day after stopping 25 mg tablets, start the 2.4 mg injection [2].

Factor 4: how much headroom does the product have?

The dose ceilings differ, and that matters if your response plateaus later.

Product	Maximum labeled dose
Wegovy injection	7.2 mg weekly for adults who tolerate 2.4 mg for 4 weeks and need more reduction
Wegovy tablets	25 mg daily
Zepbound	15 mg weekly
Foundayo	17.2 mg daily
Saxenda	3 mg daily

Wegovy’s higher-dose option is not approved for pediatric patients [2]. Zepbound’s 15 mg is the maximum for all its indications [3].

This is a fair question to raise up front: if this dose stops working in a year, what is above it?

Factor 5: tolerability and your own history

If you have taken a GLP-1 before and could not tolerate it, that history is a real input.

The pooled Zepbound weight trials recorded gastrointestinal reactions in 56 percent of treated patients versus 30 percent on placebo, with most nausea, vomiting and diarrhea occurring during dose escalation and decreasing over time [3]. Discontinuation for adverse reactions ran 4.8 to 6.7 percent versus 3.4 percent on placebo, mostly in the first few months [3].

ADA recommendation 8.20 is relevant here too: individualize the dose and the titration approach to balance effectiveness and tolerability, because “the optimal treatment dose may not be the maximum approved dose” [1]. A product you tolerate at a mid dose may serve you better than one you cannot escalate at all.

Factor 6: what else are you trying to treat?

Several of these drugs do more than one job, and stacking indications can simplify both the clinical case and the coverage case.

Type 2 diabetes plus obesity: semaglutide or tirzepatide are ADA’s named preferences [1]
Established cardiovascular disease plus obesity or overweight: Wegovy injection or tablets [2]
Chronic kidney disease plus type 2 diabetes: Ozempic injection carries a specific indication for reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death [10]
Moderate to severe obstructive sleep apnea plus obesity: Zepbound [3]
Noncirrhotic MASH with F2-F3 fibrosis: Wegovy injection [2]

Factor 7: pregnancy plans and contraception

The weight-management labels all say these drugs may cause fetal harm and should be discontinued when pregnancy is recognized. Wegovy’s label advises stopping at least 2 months before a planned pregnancy because of semaglutide’s long half-life [2]. Zepbound’s label advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [3].

Those are different practical burdens, and they belong in the choice.

What about combining or switching?

You cannot combine. Wegovy’s label states that concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended [2]. Zepbound says the same about tirzepatide-containing products and any GLP-1 receptor agonist [3]. Foundayo says concomitant use with another GLP-1 receptor agonist is not recommended [4].

Switching is normal. ADA recommendation 8.21 says that in people not reaching weight treatment goals, modify or intensify treatment with additional approaches including structured lifestyle management programs, metabolic surgery, and additional or alternative pharmacologic agents [1]. Switching within the class is an expected step, not evidence that treatment failed.

How should you frame the conversation?

ADA recommendation 8.6 says to individualize the initial approach among lifestyle and nutritional therapy, pharmacologic therapy and metabolic surgery based on the person’s medical history, life circumstances and preferences, and to consider combining approaches [1]. That is shared decision-making, and it means your input on format, frequency and cost is part of the clinical decision, not separate from it.

A useful way to open it: “Here are the indications I meet, here is what my plan covers, here is the dosing format I can actually keep up with for years. Given those three, which would you pick?”

This article summarizes what the FDA-approved prescribing information and the accompanying Instructions for Use say about each product, alongside published guideline recommendations. It does not recommend a drug, a dose, or a change to anything you are taking. Follow your own prescription, the Instructions for Use supplied with your product, and a healthcare provider who knows your history.

Sources

Questions people ask

Which GLP-1 do guidelines actually recommend?

The American Diabetes Association's 2026 Standards of Care recommendation 8.18 says that in people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a GLP-1 or dual GIP/GLP-1 receptor agonist with greater weight loss efficacy, naming semaglutide or tirzepatide, at evidence grade A. No major US guideline picks between those two for weight alone.

Is Zepbound stronger than Wegovy?

They cannot be compared from separate trials. What the ADA's Table 8.1 shows is that in the trials it summarizes for people with type 2 diabetes, tirzepatide 15 mg produced 14.7 percent weight loss from baseline at 72 weeks, while semaglutide 2.4 mg produced 9.6 percent at 56 weeks. Different trials, different durations, different populations. The head-to-head evidence is covered in the clinical trials lane.

Should I choose a pill or an injection?

It depends on practical fit more than effectiveness. Oral semaglutide requires an empty stomach in the morning, no more than 4 ounces of water, and a 30-minute wait before food, drinks or other medicines. Foundayo, the orforglipron tablet, has none of those rules. Injections are weekly for most products and daily for Saxenda.

Does insurance really drive the choice?

The ADA says so in writing. Its 2026 Standards of Care describes GLP-1 receptor agonists and tirzepatide as "the preferred agents in individuals with stable insurance coverage." Formulary position and prior authorization criteria are the most common practical deciders.

Which one should I pick if I have sleep apnea?

Zepbound is the only one in the class with an FDA indication for moderate to severe obstructive sleep apnea in adults with obesity, with maintenance doses of 10 mg or 15 mg for that use. That matters because some plans that exclude weight-loss drugs will cover it under the sleep apnea diagnosis.

Which one if I have heart disease or liver disease?

Wegovy injection carries indications for reducing major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and for noncirrhotic MASH with moderate to advanced liver fibrosis. Wegovy tablets carry the cardiovascular indication but not the MASH one.

Can I take two GLP-1s at once?

No. Every label in the class states that concomitant use with another GLP-1 receptor agonist is not recommended. Switching between products involves a defined changeover rather than an overlap.

What if the first one does not work for me?

ADA recommendation 8.21 says that in people not reaching weight treatment goals, modify or intensify treatment with additional approaches including structured lifestyle programs, metabolic surgery, and additional or alternative pharmacologic agents. Switching within the class is a normal next step, not a failure.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.